ProjectAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete…
Basic data
Title:
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group
Duration:
04/12/2015 to 03/12/2018
Abstract / short description:
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group
Keywords:
clinical trial
klinische Studie
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions
Centers or interfaculty scientific institutions
Contact persons
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine